Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo, Clear all

Conditions: Obstructive Sleep Apnea, Nasal Congestion, Sinus Congestion
Interventions: Thermosmart & placebo, Placebo Device & Nasacort, Placebo Arm; Drug · Device
Lead sponsor: Clayton Sleep Insititute; Industry
Eligibility: 16 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Sickle Cell Disease, HEMOGLOBIN SS, Hemoglobin S Beta-0 Thalassemia, Inflammation, Quality of Life
Interventions: Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA), Placebo Capsules; Dietary Supplement · Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 10 Years to 19 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Pharmacokinetics of ASKP1240, Healthy Volunteers
Interventions: ASP1240, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Atopic Immunoglobulin E-Mediated Allergic Disorder
Interventions: STMC-103H, Placebo; Biological
Lead sponsor: Siolta Therapeutics, Inc.; Industry
Eligibility: 2 Years to 40 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Stockton, California • Tustin, California

Conditions: Cortisol Resistance, Negative Feedback, ACTH, Mineralcorticoid, Glucocorticoid
Interventions: Mifepristone, Placebo, Spironolactone, Combined, Dexamethasone; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acute Pain
Interventions: Open Placebo, Opioid medication as part of standard care; Dietary Supplement · Other
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Psoriasis
Interventions: ABBV-157, Placebo for ABBV-157; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 10
States / cities: Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 7 more

Conditions: Alzheimer's Disease
Interventions: Placebo, RO5313534; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years and older
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 15
States / cities: Orange, California • Torrance, California • Norwalk, Connecticut + 11 more

Conditions: Rosacea
Interventions: CD07805/47 Gel, Placebo; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 12
States / cities: Hot Springs, Arkansas • Miami Beach, Florida • Newnan, Georgia + 9 more

Conditions: Healthy, Influenza
Interventions: FluMist; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 4
States / cities: San Diego, California • Daytona Beach, Florida • Portland, Oregon + 1 more

Conditions: Pulmonary Hypertension
Interventions: Ranolazine, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Baltimore, Maryland • Boston, Massachusetts • Philadelphia, Pennsylvania

Conditions: Prostate Adenocarcinoma
Interventions: Flibanserin 100 MG, Placebo, Androgen deprivation therapy; Drug
Lead sponsor: Andrew McDonald; Other
Eligibility: 18 Years and older · Male only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Myositis
Interventions: Nipocalimab, Placebo, Glucocorticoids; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 19
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 15 more

Conditions: Tobacco Use Disorder
Interventions: AAT-experiment, AAT-placebo; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 13 Years to 18 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Pediatric Burns
Interventions: magnesium sulfate, Normal Saline (0.9% NaCl); Drug
Lead sponsor: Hennepin Healthcare Research Institute; Other
Eligibility: 3 Years to 18 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy Volunteers, Generalized Anxiety Disorder (GAD), Bipolar Disorder (BPD)
Interventions: ABBV-932, Placebo for ABBV-932; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Los Alamitos, California • Grayslake, Illinois • Marlton, New Jersey

Conditions: Neurogenic Orthostatic Hypotension
Interventions: Sinosuidal Galvanic Vestibular Stimulation, Placebo; Device
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Tuberous Sclerosis, Neurofibromatoses, Angiofibroma, Neurofibroma
Interventions: Skincerity, Skincerity plus sirolimus/rapamycin, Skinercity plus sirolimus/rapamycin; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 13 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: AndroGel, placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 11
States / cities: Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 7 more

Conditions: Obesity
Interventions: HM11260C, Placebo; Biological
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 297 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cannabis Dependence, Marijuana Dependence
Interventions: Dronabinol, Placebo, Lofexidine; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Alzheimer's Disease
Interventions: donezepil (Aricept); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 2
States / cities: New Haven, Connecticut • Albany, New York

Conditions: PTSD
Interventions: Ketamine, TIMBER Psychotherapy, Placebo (normal saline); Drug · Behavioral
Lead sponsor: Cooper Norcross Health; Other
Eligibility: 21 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: Camden, New Jersey

Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: HM15211, Placebo of HM15211; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 48
States / cities: Huntsville, Alabama • Chandler, Arizona • Chula Vista, California + 37 more

Search by objective public record fields.

Effect of Heated Humidity With Thermosmart™ Compared to an Intranasal Steroid in Improving Compliance and Nasal Symptoms in Patients Using Continuous Positive Airway Pressure

A Randomized Trial of LOVAZA in Pediatric Sickle Cell Disease (SCD)

Study of ASKP1240 After a Single Intravenous Dose at Escalating Dose Levels in Healthy Subjects

A Phase 1b Study of STMC-103H in Multi-Sensitized Allergic Subjects Who Are Otherwise Healthy

Evaluation of Cortisol Resistance in Young Sedentary and Endurance-Trained Men

Open Label Placebo to Reduce Prescription Opioid Use

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Participants With Chronic Plaque Psoriasis

A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease

Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults

Targeting Right Ventricle in Pulmonary Hypertension Gilead

Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer

A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies

Tobacco Approach Avoidance Training for Adolescent Smokers-2

Magnesium Sulfate in Pediatric Burn Dressing Changes

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)

Sinusoidal Galvanic Vestibular Stimulation for Neurogenic Orthostatic Hypotension / Syncope

Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)

Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer

Effect of LAPS-Exendin on Body Weight in Obese Population

Combined Pharmacotherapy for Cannabis Dependency

A Randomized, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCI

TIMBER Psychotherapy and Ketamine Single Infusion in Chronic PTSD

Efocipegtrutide (HM15211) in Adults With Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)